{"name":"Merz North America, Inc.","slug":"merz-north-america-inc","ticker":"","exchange":"","domain":"merznorthamerica.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"Placebo 4-weeks","genericName":"Placebo 4-weeks","slug":"placebo-4-weeks","indication":"Other","status":"phase_3"},{"name":"NAFT500 (adult)","genericName":"NAFT500 (adult)","slug":"naft500-adult","indication":"Temporary improvement of moderate to severe glabellar lines (frown lines) in adults","status":"marketed"},{"name":"NAFT500 (pediatric)","genericName":"NAFT500 (pediatric)","slug":"naft500-pediatric","indication":"Tinea pedis (athlete's foot) in pediatric patients","status":"marketed"},{"name":"NAFT600 (adult)","genericName":"NAFT600 (adult)","slug":"naft600-adult","indication":"Temporary improvement of moderate to severe glabellar lines (frown lines) in adults","status":"marketed"},{"name":"NAFT600 (pediatric)","genericName":"NAFT600 (pediatric)","slug":"naft600-pediatric","indication":"Pediatric spasticity","status":"marketed"},{"name":"Naftin 1% Cream","genericName":"Naftin 1% Cream","slug":"naftin-1-cream","indication":"Tinea pedis (athlete's foot)","status":"phase_3"},{"name":"Naftin Cream","genericName":"Naftin Cream","slug":"naftin-cream","indication":"Other","status":"marketed"},{"name":"Placebo 2-weeks","genericName":"Placebo 2-weeks","slug":"placebo-2-weeks","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"NAFT-500","genericName":"NAFT-500","slug":"naft-500","indication":"Fungal skin infection (specific indication under phase 3 evaluation)","status":"phase_3"},{"name":"NAFT-600 ( naftin 2 % gel )","genericName":"NAFT-600 ( naftin 2 % gel )","slug":"naft-600-naftin-2-gel","indication":"Fungal skin infections (dermatophyte infections, tinea pedis, tinea cruris, tinea corporis)","status":"phase_3"}]}],"pipeline":[{"name":"Placebo 4-weeks","genericName":"Placebo 4-weeks","slug":"placebo-4-weeks","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"NAFT-500","genericName":"NAFT-500","slug":"naft-500","phase":"phase_3","mechanism":"NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions.","indications":["Fungal skin infection (specific indication under phase 3 evaluation)"],"catalyst":""},{"name":"NAFT-600 ( naftin 2 % gel )","genericName":"NAFT-600 ( naftin 2 % gel )","slug":"naft-600-naftin-2-gel","phase":"phase_3","mechanism":"Naftin is an allylamine antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.","indications":["Fungal skin infections (dermatophyte infections, tinea pedis, tinea cruris, tinea corporis)"],"catalyst":""},{"name":"NAFT500 (adult)","genericName":"NAFT500 (adult)","slug":"naft500-adult","phase":"marketed","mechanism":"NAFT500 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","indications":["Temporary improvement of moderate to severe glabellar lines (frown lines) in adults"],"catalyst":""},{"name":"NAFT500 (pediatric)","genericName":"NAFT500 (pediatric)","slug":"naft500-pediatric","phase":"marketed","mechanism":"NAFT500 is a naftifine hydrochloride topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase.","indications":["Tinea pedis (athlete's foot) in pediatric patients","Tinea cruris (jock itch) in pediatric patients","Tinea corporis (ringworm) in pediatric patients"],"catalyst":""},{"name":"NAFT600 (adult)","genericName":"NAFT600 (adult)","slug":"naft600-adult","phase":"marketed","mechanism":"NAFT600 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","indications":["Temporary improvement of moderate to severe glabellar lines (frown lines) in adults","Temporary improvement of moderate to severe lateral canthal lines (crow's feet) in adults"],"catalyst":""},{"name":"NAFT600 (pediatric)","genericName":"NAFT600 (pediatric)","slug":"naft600-pediatric","phase":"marketed","mechanism":"NAFT600 is a botulinum toxin product used to reduce muscle contractions and treat movement disorders in pediatric patients.","indications":["Pediatric spasticity","Pediatric movement disorders"],"catalyst":""},{"name":"Naftin 1% Cream","genericName":"Naftin 1% Cream","slug":"naftin-1-cream","phase":"phase_3","mechanism":"Naftin (naftifine) is a topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.","indications":["Tinea pedis (athlete's foot)","Tinea cruris (jock itch)","Tinea corporis (ringworm)"],"catalyst":""},{"name":"Naftin Cream","genericName":"Naftin Cream","slug":"naftin-cream","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo 2-weeks","genericName":"Placebo 2-weeks","slug":"placebo-2-weeks","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPdXloNVZJY2ZiaXdsX1huWXMwLUZNeXJ6RndZUFNYZTJnRGpVd3dqSnBkYVlEbzM0TWdCemdOS1BHVHB6UXFzS1ZwbGNqSEw5YllLT21qYThOSFgtX2FzbW00NmRpbnl4U05vcDNCN0FpYlh1SGo2VTB1UGQ1VHZ0Ty1Jbk4ybDNvT2RkalRvMDgyLTlndnUtTlJScTVPY0RtSnBPNS1DUS1zUTlQcUZFQmYzVnFBRmZaMXFDalZmR3ctelhQZEYwc2tEQmg5NU14VGlITnZYV3FPQmdGVkNNUjBPSDdpcHZQelU2djF3?oc=5","date":"2026-04-08","type":"regulatory","source":"businesswire.com","summary":"Merz Aesthetics Receives FDA Approval for RADIESSE® for the Treatment of Wrinkles in the Décolleté Area - businesswire.com","headline":"Merz Aesthetics Receives FDA Approval for RADIESSE® for the Treatment of Wrinkles in the Décolleté Area","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPYjdFelBfN0FrcWRpdlo0LWQ1UHdtclhXWXZqOGdnUXd1VTFJbDBvR0QyRGlFcWJPcFk4Z2pzc3piNkV2eWo5QWxjckdQbFUxX1ozVURsU19uQmZMZEh1MG1YQmtEclR3TGZ5VmhGYUpFQXpsdlcyU2lCemk4TFR6MGxyQkt4S0QxakczcDRsTGNxeUJ5UkhDU3dFR1puSVdhbUFOa2xycw?oc=5","date":"2026-02-10","type":"deal","source":"CSRwire","summary":"Merz Aesthetics Extends Partnership With North Carolina Women’s Soccer Team - CSRwire","headline":"Merz Aesthetics Extends Partnership With North Carolina Women’s Soccer Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPVFltbjB6ZURzNDNGQk1XY2dPZkxWZ0hsTXBaQ2J0Y0d2VHcycEtYSE01eXNBamxHVFJ4a0VEcEItZzNBd1NSSkxWVW1FZThGQW1yVkk3amZrWjBSalk4WG5UZ1AyM2NHaUlTbGFQS2t4Skdfb2J6c29yNV8xcXJwb0ZOVE1SaFVQTUNBT1Fvanh1SzNRa1E3VzZabmV2d2x3RkE?oc=5","date":"2025-08-01","type":"pipeline","source":"Fierce Pharma","summary":"Merz Aesthetics gives sales and marketing leadership a face-lift - Fierce Pharma","headline":"Merz Aesthetics gives sales and marketing leadership a face-lift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxNMUtmRzQtOUl4OEJMQi1XOXQ0dWM1Y3BOTzF1aVhqMUVhdTRZQ21JNW9vZVhpWUpKMW1CVzUtSWlaS3NtaXJubmZ2U0pkWWI1ODl5MmZtczFhQlNDVU9lX2JfN2dLeWR0NWlQc0VzdDM0S3JlSlU3QVZhUHNWblNfN1V3RHZKN2M4U2poSzI4Y0ZIbGxtX1J0ZjNmeExldmxma1M2TVBnWG5vTE5ZRlZHRnNFZjVBSHBWdTdtLUxFbk9TT1JISjQ4NExIdnh6VVJnbVA4UWdyQ19jdWFkQVdwdHVISmlrTWtLVDlTdmVUQzIydjZxX1c4REl0QWhwX0st?oc=5","date":"2025-01-29","type":"trial","source":"businesswire.com","summary":"Merz Aesthetics Reveals Global Data on the Connection Between Confidence, Self-Affirmation and Aesthetic Treatments - businesswire.com","headline":"Merz Aesthetics Reveals Global Data on the Connection Between Confidence, Self-Affirmation and Aesthetic Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1SV1JLcEI1TjlERlIzd3Z0emIwYzA3Q2Ftbzk0VWVsZWdYTTZnSU5Hd2VNYnlxV3hqdGcyeWNoYWpTSTcxVUlwRk5Nd3BUS0xZTmowOHFQRy1qZmJTTDdxSTdfNk10bnFodjc0SQ?oc=5","date":"2024-07-18","type":"pipeline","source":"Market.us Media","summary":"Top 10 Medical Aesthetics Companies | By Experienced Medical Practitioners - Market.us Media","headline":"Top 10 Medical Aesthetics Companies | By Experienced Medical Practitioners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNbVZ1RGR3dGpsdHZFM1FEeFpjOFhKVXVSVzdOWGVBS3ZOSThVVXBzS1JzLTJGYnlhMnc0RGJnSmZuYTJ3WC1GVHhEb0dFLTQ1cU5wVEhiMkM3OFQzQ1lBMEFCT094S2kxaHdjdG5IZi1jdllGQjJKYXBrOVdYN1kyNXk3ZVBsM08tREthM2dMalZ3V2FVTWpaZkJWbXBXWTdfLWhHWg?oc=5","date":"2024-05-16","type":"pipeline","source":"Bloomberg Law News","summary":"Merz Pharma Wins Injunction Against Ex-Employee Who Took Info - Bloomberg Law News","headline":"Merz Pharma Wins Injunction Against Ex-Employee Who Took Info","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPUXlYYldwSF9EMTFXUlpkSEdlMDAyQzZIT2FVZ2FCcm5QS0dTalE4cjdoNDY3a3BnQTVEbHNHTjQ2Qm1YV2wydG5MS1Bic2wtbUp6cWNWeFYyeEo4aDQxTUhjMVFkMFJvQmxJTnFSUUhtdjhaNTltVGlFNmFRUHFCUU1zQWVUNGFnOFpTZDh3MkFNRUdla1dXNTI4WjJPSk9VMmNLcEJoR053R3lYLVk1eUtwNjNFRHpheEhHd2F0NVNxZw?oc=5","date":"2024-04-09","type":"pipeline","source":"Fierce Pharma","summary":"UPDATED: Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales - Fierce Pharma","headline":"UPDATED: Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5vWURTN3lueWtBVHJXMzBCUTAxYXJRWGRRZ0lqcFJZVjlQQlZya1BsU3NHczI0ZmNjOF92WHJTeV8tZnJyOElGYjNET3VFXzZVNnEzT3hYU2VoY2x2MlRPMjZ0YU43TVpSRW93alUyMDBHQjFicmZGaU1vaWR4SjA?oc=5","date":"2024-04-02","type":"deal","source":"businessnc.com","summary":"Merz Therapeutics buying two drugs for $185 million - businessnc.com","headline":"Merz Therapeutics buying two drugs for $185 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPUGtZNldMbVhhT2J1NVdxbXNNTlZuSnpnc2djai1QTERJcWw1RU9BYjJybElQb3ZGU3plcXMweHM5NGJ0MUd0QXI0S213Ync0MUZra3A0WGtwemdpaWNMWG9IdklwMVZNWjJscjV3Uk41XzdKck5VZE9fTUhHTGlVMm5lWlVzUHFmSl9EWU04blo0MHRGTXdfSFR3ckZCLXFsa1E?oc=5","date":"2024-04-02","type":"pipeline","source":"The Business Journals","summary":"Merz offers $185 million for assets of bankrupt biotech - The Business Journals","headline":"Merz offers $185 million for assets of bankrupt biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQVkE5MmdnZU9URjE4d29ESkZYdHBuZ1lJNFBFVy1xZ082ZFJ4Z0xBSy1PM2piWDRjaWV4SXZhODgyWl8yakZiVjVoY3BzMXhsbHRvTnJka0Q1MlZhbUFpQzVMdHgtd3c0alpvTU5NazdQaXNPY0RoOTd1bzRZOEtnZmVyanQ5Rm5sTDBGMA?oc=5","date":"2022-05-16","type":"pipeline","source":"Yahoo Finance","summary":"Global Cerebral Palsy Treatment Market Report to 2030 - Featuring Merz Pharmaceuticals, Pfizer, Bayer and Johnson & Johnson Among Others - Yahoo Finance","headline":"Global Cerebral Palsy Treatment Market Report to 2030 - Featuring Merz Pharmaceuticals, Pfizer, Bayer and Johnson & John","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcWFhdXVpSklOeGRvVjd0SVhVVy05MGtBOG1JTkU5aUVENmJWWUg2Vm15a2Y3YkZxbVVGNmR0dFM2STl3V2RGdWJmNWZrS0lDajZyUktjbkVwdXRJQmN2VjJ6ZHN6TFN0ZnBWMHN3a0tjY1pYNkJtdkQwTHN3QUQyWkJFbk9BUEtxVl9UYnh3NGpHRjZHektyOERMN1JfbkJuRkExTkFXZ1A4Q3dibk5xSlpyUmVkUXdSOURN?oc=5","date":"2019-11-12","type":"regulatory","source":"glossy.co","summary":"'Tweakments instead of treatments': Merz Pharma restructures to meet beauty consumer demands - glossy.co","headline":"'Tweakments instead of treatments': Merz Pharma restructures to meet beauty consumer demands","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQMHhFblYzN195UUo5Q1JJWU1UUmJUVm1DQlNTOUV6czhRcXlpWTVKTE9iRElEVlI1YzZnLWtsbEREZmtXX3ZlSVpod012bGZFOEUtb2xJMVhUTGE4OWtyTnNtcTJTYXlDZ3JaUXZ0V0xTUGFSRmpUdGx5T1pXbC1xSE5nZEFvdFg5UUJlMXFsdkdIZ3V6SU1QQ3BEV0tTWjY5TDNV?oc=5","date":"2013-01-11","type":"pipeline","source":"Hospital Pharmacy Europe","summary":"Merz North America announces end of court-ordered injunction - Hospital Pharmacy Europe","headline":"Merz North America announces end of court-ordered injunction","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":5,"marketed":5},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}